Referenties

Biton V, Bourgeois BF; YTC/YTCE Study Investigators. Topiramate in patients with juvenile myoclonic epilepsy. Arch Neurol. 2005 Nov;62(11):1705-8. PubMed PMID: 16286543.

Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C, Kalviainen R, Mattson R, Perucca E, Tomson T (2006). ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 47(7):1094-120.

Levisohn PM, Holland KD (2007). Topiramate or valproate in patients with juvenile myoclonic epilepsy: a randomized open-label comparison. Epilepsy Behav 10: 547-52.

Liu, J., Wang, L. N., & Wang, Y. P. (2015). Topiramate monotherapy for juvenile myoclonic epilepsy. Cochrane Database Syst Rev, 12, CD010008. doi: 10.1002/14651858.CD010008.pub2

Liu, J., Wang, L. N., & Wang, Y. P. (2017). Topiramate monotherapy for juvenile myoclonic epilepsy. Cochrane Database Syst Rev, 4, Cd010008. doi: 10.1002/14651858.CD010008.pub3. 

Mantoan L,  Walker M (2011). Treatment options in juvenile myoclonic epilepsy. Curr Treat Options Neurol 13: 355-70.

National Clinical Guideline Centre (2012). Diagnosis and management of the epilepsies in adults and children in primary and secondary care.63-5.

Park K.M., Kim S.H., Nho S.K., Shin K.J., Park J., Ha S.Y., Kim S.E. A randomized open-label observational study to compare the efficacy and tolerability between topiramate and valproate in juvenile myoclonic epilepsy. Journal of Clinical Neuroscience 2013 20;1079-82.

Raspall-Chaure M, Neville B, Scott RC (2008). The medical management of the epilepsies in children: conceptual and practical considerations. Lancet Neurol. 7(1):57-69.

Sundquist A., Tomson T, Lundkvist B (1998). Valproate as monotherapy for juvenile myoclonic epilepsy: dose effect study. Ther Drug Monitor 20: 149-57. 

Thomas P, Valton L, Genton P (2006). Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsy. Brain 129:1281-92.